CLAIMS:

1. A pharmaceutical composition, comprising

   (a) at least one liposome having a particle forming component selected from the group consisting of (i) phospholipid and (ii) a mixture of at least one phospholipid and cholesterol;

   (b) at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, wherein the polyvalent counterion donor is dextran sulfate;

   (c) at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, wherein the monovalent counterion donor is sulfate; and

   (d) an amphipathic therapeutic agent, a derivative thereof, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of the monovalent counterion donor is consisting of: (i) a sulfate; and (ii) a cationic ion, wherein the sulfate is ionically paired with the cationic ions.

3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically acceptable salt of the polyvalent counterion donor is consisting of: (i) a dextran sulfate; and (ii) a cationic ion, wherein the dextran sulfate is ionically paired with the cationic ions.

4. The pharmaceutical composition of claim 2 or 3, wherein the cationic ion comprises at least one cationic ion selected from the group consisting of calcium ion, magnesium ion, sodium ion, potassium ion, manganese ion, and NR_4^+, wherein R is H or an organic residue, and mixtures thereof.

5. The pharmaceutical composition of claim 4, wherein the cationic ion is ammonium.

6. The pharmaceutical composition of claim 3, wherein the sulfate group of the dextran sulfate is at an amount of about 1 milliequivalents (mEq) to about 320 mEq per liter.

7. The pharmaceutical composition of claim 3, wherein the sulfate group of the dextran sulfate is at an amount of about 1 mEq to about 250 mEq per liter.

8. The pharmaceutical composition of claim 3, wherein the sulfate group of the dextran sulfate is at an amount of about 1 mEq to about 160 mEq per liter.

9. The pharmaceutical composition of according to any one of claims 1 to 8, wherein the pharmaceutically acceptable salt of the polyvalent counterion donor is sodium dextran sulfate or ammonium dextran sulfate.

10. The pharmaceutical composition of according to any one of claims 1 to 9, wherein dextran sulfate has a molecular weight about 1,600 daltons to about 8,000 daltons.

11. The pharmaceutical composition of according to any one of claims 1 to 10, wherein the concentration of the monovalent counterion donor is about 100 mM to about 500 mM.

12. The pharmaceutical composition of according to any one of claims 1 to 10, wherein the concentration of the monovalent counterion donor is about 150 mM to about 450 mM.

13. The pharmaceutical composition of according to any one of claims 1 to 5 or 9 to 12, wherein the concentration of the polyvalent counterion donor is about 0.1 mM to less than about 10 mM.

14. The pharmaceutical composition according to any one of claims 1 to 5 or 9 to 12, wherein the concentration of the polyvalent counterion donor is about 0.1 mM to less than about 3 mM.

15. The pharmaceutical composition of according to any one of claims 1 to 14, wherein the amphipathic therapeutic agent is a vinca alkaloid.

16. The pharmaceutical composition of according to any one of claims 1 to 14, wherein the therapeutic agent is a topoisomerase inhibitor.

17. A pharmaceutical composition, comprising at least one liposomes having:

    (a) a particle forming component selected from a phospholipid or a mixture of at least one phospholipid and cholesterol;

(b) 0.1 mM to 10 mM dextran sulfate or a pharmaceutically acceptable salt thereof;

(c) 150 mM to 450 mM sulfate or a pharmaceutically acceptable salt thereof; and

(d) a vinca alkaloid.

18. The pharmaceutical composition of claim17, wherein the sulfate or a pharmaceutically acceptable salt thereof is ammonium sulfate.

19. The pharmaceutical composition of claim17 or 18, wherein the liposome further comprises a hydrophilic polymer.

20. A liposome, comprising:

(a) a particle forming component selected from a phospholipid or a mixture of at least one phospholipid and cholesterol;

(b) 0.1 mM to 10 mM dextran sulfate or a pharmaceutically acceptable salt thereof; and

(c) 150 mM to 450 mM sulfate or a pharmaceutically acceptable salt thereof.

21. The liposome of claim 20, wherein the sulfate or a pharmaceutically acceptable salt thereof is ammonium sulfate.

22. The liposome of claims 20 or 21, wherein dextran sulfate has a molecular weight about 1,600 daltons to about 8,000 daltons.